Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography

Autor: James C. Engert, Raphaëlle Bourgeois, Patrick Mathieu, Philippe Pibarot, Yohan Bossé, Maxime Nadeau, Sotirios Tsimikas, Michel Tessier, Mikaël Trottier, Mylène Shen, George Thanassoulis, Joseph L. Witztum, Marc R. Dweck, Audrey-Anne Després, Sébastien Thériault, Lionel Tastet, Marie-Annick Clavel, Jean Guimond, Patrick Couture, Benoit J. Arsenault, Anthony Poulin, Hao Yu Chen, Nicolas Perrot
Rok vydání: 2019
Předmět:
Aortic valve
lcsh:Diseases of the circulatory (Cardiovascular) system
medicine.medical_specialty
030204 cardiovascular system & hematology
Cardiovascular
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Clinical Research
Interquartile range
Internal medicine
Sodium fluoride
medicine
030304 developmental biology
screening and diagnosis
0303 health sciences
biology
medicine.diagnostic_test
business.industry
Calcific aortic valve stenosis
Lipoprotein(a)
3. Good health
Detection
medicine.anatomical_structure
chemistry
lcsh:RC666-701
Positron emission tomography
biology.protein
Cardiology
cardiovascular system
Original Article
Microcalcification
medicine.symptom
Cardiology and Cardiovascular Medicine
business
4.2 Evaluation of markers and technologies
Lipoprotein
Zdroj: CJC Open
CJC open, vol 1, iss 3
CJC Open, Vol 1, Iss 3, Pp 131-140 (2019)
ISSN: 2589-790X
Popis: Background: Lipoprotein(a) (Lp[a]) is the preferential lipoprotein carrier of oxidized phospholipids (OxPLs) and a well-established genetic risk factor for calcific aortic valve stenosis (CAVS). Whether Lp(a) predicts aortic valve microcalcification in individuals without CAVS is unknown. Our objective was to estimate the prevalence of elevated Lp(a) and OxPL levels in patients with CAVS and to determine if individuals with elevated Lp(a) but without CAVS have higher aortic valve microcalcification. Methods: We recruited 214 patients with CAVS from Montreal and 174 patients with CAVS and 108 controls from Québec City, Canada. In a second group of individuals with high (≥75 nmol/L, n = 27) or low (
Databáze: OpenAIRE
Externí odkaz: